Primaquine product description

Primaquine, it is released in the form of diphosphate. It is a fine crystalline powder of a bright yellow color, bitter in taste, soluble in water. It has an antiprotozoal effect on the sexual forms, schizonts and para-erythrocytic forms of all forms of malaria plasmoids. Applied for the prevention of long-term recurrences with three- and four-day and tropical malaria. In addition, prescribed for personal chemoprophylaxis in combination with Chingaminum (chloroquine), as well as for public chemoprophylaxis.

Primaquine safety information

Among the population of some areas of the Mediterranean, the Caucasus, and Africa (particularly often) there are people with congenital lack of glucose-6-phosphate dehydrogenase, therefore in these areas the primaquine should be consumed with an extreme caution, not exceeding the daily dose of 0.015 g based on the base (0.027 g diphosphate) for an adult; in the process of treatment, the accurate monitoring of the patient is necessary.

Primaquine should not be taken simultaneously with the Acrichinum (the Primaquine tablet is retained in the blood, and therefore its toxicity enhances) and during the shortest time after taking the Acrichinum (due to the slow release of Acrichinum from the body) and also with drugs that can exert hemolytic action and inhibit myeloid elements bone marrow (sulfonamides, etc.).

Primaquine is contraindicated for persons with acute infectious diseases (except malaria), during an exacerbation of rheumatism and other diseases characterized by a tendency to granulocytopenia, with blood and hematopoietic diseases, kidney illness, angina pectoris. It is impossible to cure with a help of Primaquine simultaneously with drugs that depress hemopoiesis.

Primaquine side effects

In the majority of cases this medical agent is well tolerated, but occasionally during the course of pharmaceutical, there may appear the pain in the abdomen, dyspepsia, pain in the heart; general weakness, cyanosis (methemoglobinemia). These phenomena occur after the drug course is discontinued. Children should get the prescription just being under severe control during the treatment procedure. An acute intravascular hemolysis with the hemoglobinuria may manifest in people with a lack of erythrocyte in the enzyme glucose-6-phosphate dehydrogenase. In severe cases, the picture resembles hemoglobinuric fever.

When prescribing the Primaquine tablets to patients with symptoms of anemia and with suspicion of anemia, an abnormality of red blood cells should be carefully regulated and the examination of the state of the blood and urine should be conducted as well. At the first signs of a change in the color of urine, a sharp decrease in the content of hemoglobin or a change in the number of white blood cells, the course of the treatment with Primaquine has to be immediately canceled.